{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T10:29:37Z","timestamp":1722508177409},"reference-count":0,"publisher":"Pensoft Publishers","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p><jats:bold>Background:<\/jats:bold> Familial hypercholesterolaemia (FH) is a genetic disorder causing accelerated atherosclerosis and premature cardiovascular disease (CVD). This retrospective observational study examined the clinical characteristics and management of FH subjects in Bulgaria over a 12-month period.<\/jats:p>\n<jats:p><jats:bold>Materials and methods:<\/jats:bold> Twelve cardiology sites participated in this study from May 2015 to May 2016. Eligible subjects had at least two routine low-density lipo-protein cholesterol (LDL C) measurements and a prescription for lipid-lowering therapy (LLT) at the start of the observation period. Mean values for gender, age and cardiovascular (CV) event history at baseline and LDL-C over time were estimated.<\/jats:p>\n<jats:p><jats:bold>Results:<\/jats:bold> Of the 220 eligible subjects, 196 fulfilled the criteria for FH diagnosis: 27 definite, 94 probable and 75 possible. Mean age at enrolment was 54.4 years and 64.1% of subjects were male. Mean CV risk classification at baseline was 26.8% high-risk (HR) and 73.2% very high-risk (VHR). Mean LDL-C was 5.6 mmol\/L at enrolment and 4.1 mmol\/L at last observation visit (12 months). The ESC\/EAS Guideline LDL-C targets (applicable at the time of the study) were achieved by 14.5% of HR and 5.0% of VHR subjects. Most subjects (n=219) received statins. One subject was statin intolerant (ezetimibe therapy). Intensive statin treatment (atorvastatin 40\u201380 mg\/daily and rosuvastatin 20\u201340 mg\/daily) was used in 38.6% of individuals during the observation period and 10% of subjects received combination therapy (statin plus ezetimibe or other LLT).<\/jats:p>\n<jats:p><jats:bold>Conclusions:<\/jats:bold> Most subjects with FH do not reach the ESC\/EAS defined LDL-C targets. Early identification and physician education may improve FH management.<\/jats:p>","DOI":"10.2478\/folmed-2018-0020","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T17:15:35Z","timestamp":1540487735000},"page":"389-396","source":"Crossref","is-referenced-by-count":4,"title":["Management of High and Very High-Risk Subjects with Familial Hypercholesterolemia: Results from an Observational Study in Bulgaria"],"prefix":"10.3897","volume":"60","author":[{"given":"Ivo S.","family":"Petrov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arman Sh.","family":"Postadzhiyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariya P.","family":"Tokmakova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lyudmila G.","family":"Kitova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Svetlin N.","family":"Tsonev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janet","family":"Addison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reneta T.","family":"Petkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasil I.","family":"Lachev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2258","container-title":["Folia Medica"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/folmed.2018.60.issue-3\/folmed-2018-0020\/folmed-2018-0020.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.degruyter.com\/view\/j\/folmed.2018.60.issue-3\/folmed-2018-0020\/folmed-2018-0020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T18:37:02Z","timestamp":1565807822000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.degruyter.com\/view\/j\/folmed.2018.60.issue-3\/folmed-2018-0020\/folmed-2018-0020.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,1]]},"references-count":0,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.2478\/folmed-2018-0020","relation":{},"ISSN":["1314-2143"],"issn-type":[{"value":"1314-2143","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,1]]}}}